TITLE

Juvaris Gets $25M to Advance Flu Vaccine

PUB. DATE
September 2009
SOURCE
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the 25 million dollars Series B financing completed by Juvaris BioTherapeutics Inc. for its advance influenza vaccine program in Burlingame, California. It states that Juvaris has completed the fund which they will be used for the midstage clinical development of its influenza vaccine candidate JVRS-100. It adds that the company is making add-on vaccines that will help advance the effect of the current vaccines on the seasonal and pandemic influenza.
ACCESSION #
44369836

 

Related Articles

  • Juvaris Gets $25M in Series B to Advance Add-on Flu Vaccine. Hollingsworth, Catherine // BioWorld Today;9/18/2009, Vol. 20 Issue 180, p1 

    The article reports on a 25 million U.S. dollars Series B financing completed by Juvaris BioTherapeutics Inc. Proceeds of the financing will be used by the company to fund midstage clinical development of lead vaccine candidate JVRS-100 for seasonal and pandemic influenza. The vaccines are...

  • NIH awards for vaccine development.  // PharmacoEconomics & Outcomes News;3/25/2006, Issue 499, p11 

    Deals with the grants awarded by the U.S. National Institutes of Health for vaccine research and development in March 2006. Development of an immunostimulant needle-free patch by Iomai Corp.; Test of a novel vaccine directed against HIV infections by Juvaris BioTherapeutics.

  • Financings Roundup.  // BioWorld Today;1/28/2010, Vol. 21 Issue 18, p3 

    The article reports on the completion of the second part of its Series B equity financing of up to 25 million U.S. dollars by Juvaris BioTherapeutics Inc.

  • Other News To Note.  // BioWorld Today;9/12/2011, Vol. 22 Issue 176, p2 

    The article presents news briefs on the U.S. pharmaceutical industry, including a licensing deal between Juvaris BioTherapeutics Inc. and Colby Pharmaceutical Co., the completion of initial technology transfer by PharmAthene Inc., and the offer of Valeant Pharmaceuticals International Inc. to...

  • CLINIC ROUNDUP.  // BioWorld Today;4/28/2009, Vol. 20 Issue 80, p5 

    This section offers news briefs on biotechnology industry. AnaMar Medical AB has received approval from the British Medicines and Healthcare products Regulatory Agency to initiate clinical trials for the oral drug AMAP102. Discovery Laboratories Inc. has released data analysis from its clinical...

  • Leukemia Update.  // PharmaWatch: Cancer;Nov2006, Vol. 5 Issue 11, p6 

    The article focuses on various developments in the pharmaceutical industry directed towards the treatment of leukemia. Bioenvision Inc.'s drug Evoltra has potential to improve survival rates in children with relapsed/refactory acute leukemia. A study will be conducted by EntreMed to examine the...

  • Correction.  // Contemporary Pediatrics;Aug2003, Vol. 20 Issue 8, p17 

    Presents a correction to a statement about flu vaccine in the column "Updates" that was previously published in the June 2003 issue.

  • Beware: The Beijing flu is coming. Butler, Robert N. // Geriatrics;Sep93, Vol. 48 Issue 9, p17 

    Editorial. Cautions against the Beijing strain of influenza A virus that is anticipated to hit the United States. Inclusion of mutated Beijing strain in vaccine; Main classes of influenza virus; Increase in genetically mixed influenza A viruses; Estimated number of people who die during flu...

  • Easy flu season ahead? Liebman, Milton // Medical Marketing & Media;Dec2002, Vol. 37 Issue 12, p20 

    Reports on the availability of a flu vaccine in physician's offices in the U.S. Number of doses available; Aim of reducing the risk of contracting flu; Impact of the leftover vaccine on the manufacturers.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics